|[September 06, 2013]
Research and Markets: Apoptosis in Oncology Drug Pipeline Update 2013: Apoptotic Pathways Provide Exciting Molecular Targets for New Therapeutic Agents to Specifically Promote Apoptosis of Cancer Cells
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/zr79pq/apoptosis_in)
has announced the addition of the "Apoptosis
in Oncology Drug Pipeline Update 2013" report to their offering.
There are today 330 companies plus partners developing 402 apoptotic
drugs in 1766 developmental projects in cancer. In addition, there are
10 suspended drugs and the accumulated number of ceased drugs over the
last years amount to another 187 drugs. Apoptosis In Oncology Drug
Pipeline Update lists all drugs and gives you a progress analysis on
each one of them. Identified drugs are linked to 275 different targets.
All included targets have been cross-referenced for the presence of
mutations associated with human cancer. To date 266 out of the 268
studied drug targets so far have been recorded with somatic mutations.
The software application lets you narrow in on these muations and links
out to the mutational analysis for each of the drug targets for detailed
information. All drugs targets are further categorized on in the
software application by 62 classifications of molecular function and
with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Drug Pipeline Update at a Glance
Includes more than 330 principal companies plus their collaborators.
There is direct access from inside the application to web pages of all
This Drug Pipeline Update contains 402 apoptotic drugs in development,
which have a total of 1766 developmental projects in cancer. In addition
there are suspended and ceased drugs.
All targets are cross-referenced with the Catalogue of Somatic Mutations
in Cancer (COSMIC). It is designed to store and display somatic mutation
information and related details and contains information relating to
human cancers. To date 266 out of the 268 studied drug targets so far
have been recorded with somatic mutations and the software application
lets you narrow in on these mutations and links out to the mutational
analysis for each of the drug targets for detailed information.
The identity of available biological structures on 192 drug targets was
retrieved from the RCSB Protein Databank for you to easily review the
3486 structures available today among drug targets.
For more information visit http://www.researchandmarkets.com/research/zr79pq/apoptosis_in
About Research and Markets
Research and Markets is the world's leading source for international
market research reports and market data. We provide you with the latest
data on international and regional markets, key industries, the top
companies, new products and the latest trends.
[ Back To Technology News's Homepage ]